胆管癌治疗困境有望打破,多款创新疗法迎来胆管癌治疗新希望!

2022-08-14 Dr HopeNoah 厚朴方舟

虽然胆管癌的恶性程度较高,但手术治疗、质子治疗、靶向治疗、免疫治疗等创新疗法的出现为胆管癌患者提供了新的选择,也为患者带来了新的希望。

胆管癌是一种恶性程度极高的肿瘤,多年来胆管癌的死亡率一直居高不下,如何提高胆管癌的预后效果,延长患者的生存期十分关键。近年来,随着手术治疗、质子治疗、靶向治疗等多种创新疗法的出现,胆管癌的治疗也迎来了新的方向。

胆管癌的根治手段:手术治疗

目前根治性手术切除是治疗胆管癌的主要手段,也是胆管癌患者获得长期生存的重要方法。

根据肿瘤发生部位不同,胆管癌可分为肝内胆管癌、肝门部胆管癌和远端胆管癌,三种胆管癌的手术方式也有一定的差异,但无论是哪种胆管癌,都可以在手术切除后获得良好的预后。

  • 肝内胆管癌:肝内胆管癌的手术方式与原发性肝癌类型,均采用肝切除术治疗。由于肝内胆管癌往往不伴有肝硬化,肝脏储备功能良好,因此积极采用根治性肝切除术可以让患者获得长期的生存。

  • 肝门部胆管癌:肝门部胆管癌手术涉及门静脉、肝动脉、胆管三个管道系统,被称为普外科手术的珠穆朗玛峰。同时,由于肿瘤发现时多已侵犯肝门部重要结构,肝门部胆管癌手术切除率较低,但是,手术切除的效果显著,因此对于肝门部胆管癌患者仍应优选手术治疗。

  • 远端胆管癌:手术切除是远端胆管癌唯一可以获得根治的手段,与肝门部或肝内胆管癌相比,远端胆管癌的可切除率最高。远端胆管癌手术常采用胰十二指肠切除术(Whipple's手术)。

另外,新辅助治疗及转化治疗的出现可以显著提高胆管癌手术的可切除率,让一些原本无法完全切除肿瘤的胆管癌患者有望实现根治,进一步提高患者的预后效果。

  • 2015年的一项研究揭露,针对肝门部胆管癌或远端胆管癌,采用新辅助放化疗治疗后,R0 切除率达到 80.9%[1]。

  • 2018年的一项研究表明,对于初始不可切除的局部晚期胆管癌采用放化疗后,73.3%的患者被判定为可切除胆管癌,并接受了根治性肝切除术(60%的患者实现了R0切除),在接受手术切除的患者中,中位生存时间为37个月,1 年、2 年和 5 年生存率分别为 80.8%、70.7% 和 23.6%[2]。

▲图源:参考来源[2]

总而言之,胆管癌治疗的首选手段仍然是手术切除,但是胆管癌尤其是肝门部胆管癌手术难度大、危险性高,对医生技术水平要求极高,并非所有医院都可开展。因此,胆管癌患者选择手术经验丰富的专家治疗十分关键。

肝内胆管癌的重要放疗手段:质子治疗

肝内胆管癌是常见的胆管癌类型,也是常见的肝脏恶性肿瘤之一,放射治疗是肝内胆管癌主要的治疗手段。质子治疗作为一种新兴的放疗手段,可以将更多的放射剂量集中于病灶部位,治疗的效果更加显著且对人体正常组织造成的伤害更小,有效降低了放疗对人体造成的毒副作用。

2018年一项前瞻性II期研究报道了高剂量适形质子治疗胆管癌的突出效果。研究结果显示,质子治疗肝内胆管癌的2年肿瘤局部控制率和总生存率分别为94%和47%[3]。

▲图源:NIH

胆管癌的创新疗法:靶向治疗

由于胆管癌在早期多无特异性症状,患者常在确诊时即为晚期,失去手术机会,药物治疗是主要的治疗手段。此前,化疗是晚期胆管癌的主要手段,但是化疗的效果不佳,且常常出现耐药。

自2020年4月,首款胆管癌靶向药Pemazyre(培米替尼)获美国 FDA 批准上市后,胆管癌的靶向治疗迎来了突破性进展,为胆管癌患者提供了新的治疗选择。

▲图源:FDA

目前,已有三款胆管癌靶向药物获批于临床:

  • Pemazyre:2020年4月,Pemazyre率先获得美国FDA批准,用于治疗先前已接受过治疗、存在FGFR2融合或重排、不能手术切除的局部晚期或转移性胆管癌患者;2021年3月日本厚生劳动省(MHLW)批准[4]。推荐阅读:重磅!胆管癌首款靶向药已在日本各大医院上架,延长生存期近3倍

  • Truseltiq:2021年6月,美国食品和药物管理局(FDA)已加速批准Truseltiq(infigratinib),用于治疗先前接受过治疗、携带FGFR2融合或重排的局部晚期或转移性胆管癌(CCA)患者[5]。

  • Tibsovo:2021年8月,FDA批准靶向治疗药物Tibsovo(ivosidenib)用于治疗携带IDH1突变的局部晚期或转移性胆管癌成人患者,成为首个获批用于治疗这一患者群体的靶向疗法[6]。

有望改善晚期胆管癌效果:免疫疗法

相比进展颇丰的胆管癌靶向治疗,胆管癌的免疫治疗目前仅有一款药物的效果显著优于传统疗法。

2021年11月,针对胆管癌一线免疫治疗的TOPAZ-1 3期试验结果公布,此次数据表明,抗PD-L1疗法Imfinzi(英飞凡,通用名:durvalumab,度伐利尤单抗)联合化疗显著延长了胆管癌患者的总生存期(OS)、无进展生存期(PFS),显著提高有效率(ORR)[7]。

今年更新的第1版胆管癌NCCN指南中新增Imfinzi+吉西他滨+顺铂作为胆管癌的一线治疗(2B类证据)和二线治疗方案(2B类证据)[8]。

▲图源:参考来源[8]

虽然胆管癌的恶性程度较高,但手术治疗、质子治疗、靶向治疗、免疫治疗等创新疗法的出现为胆管癌患者提供了新的选择,也为患者带来了新的希望。相信随着临床研究的深入开展,将会有越来越多的创新疗法获批于临床,让更多胆管癌患者受益。

美国麻省总医院是美国最大的胆道疾病治疗医院之一,也是美国首屈一指的胆管癌治疗医院。在《美国新闻与世界报道》发布的2021-22年度最佳医院排名中, 麻省总医院排名前五。

在放射治疗领域,麻省总医院是美国最早的胃肠道放射肿瘤专科,也是国际公认的胃肠放射肿瘤专科领导者,该科室拥有世界先进的质子治疗、可以专门用于术中放射治疗的技术、4DCT扫描等放疗技术;在研究领域,麻省总医院积极参与胆管癌相关的临床试验和研究,可以尽快为患者带来有希望的新疗法。

参考来源:

[1]A review of current adjuvant and neoadjuvant systemic treatments for cholangiocarcinoma and gallbladder carcinoma

https://hrjournal.net/article/view/4387#B55

[2]Sumiyoshi T, Shima Y, Okabayashi T, Negoro Y, Shimada Y, Iwata J, Matsumoto M, Hata Y, Noda Y, Sui K, Sueda T. Chemoradiotherapy for Initially Unresectable Locally Advanced Cholangiocarcinoma. World J Surg. 2018 Sep;42(9):2910-2918. doi: 10.1007/s00268-018-4558-1. PMID: 29511872.

[3]Badiyan SN, Hallemeier CL, Lin SH, Hall MD, Chuong MD. Proton beam therapy for gastrointestinal cancers: past, present, and future. J Gastrointest Oncol 2018;9(5):962-971.

[4] インサイト・コーポレーション、ペマジール:registered:(ペミガチニブ)の国内製造販売承認取得を発表

https://prtimes.jp/main/html/rd/p/000000004.000060544.html

[5] BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQTM (infigratinib) for Patients with Cholangiocarcinoma.

[6] Servier Announces FDA Approval of TIBSOVO:registered: (ivosidenib tablets) in IDH1-Mutated Cholangiocarcinoma

https://www.prnewswire.com/news-releases/servier-announces-fda-approval-of-tibsovo-ivosidenib-tablets-in-idh1-mutated-cholangiocarcinoma-301363055.html

[7] Imfinzi plus chemotherapy significantly improved overall survival in 1st-line advanced biliary tract cancer in TOPAZ-1 Phase III trial at interim analysis

https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/imfinzi-improved-survival-in-biliary-tract-cancer.html

[8]2022.v1《NCCN肿瘤学临床实践指南:胆管癌》

- END -

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1970041, encodeId=4a2e19e00413f, content=<a href='/topic/show?id=ec345834075' target=_blank style='color:#2F92EE;'>#新希望#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58340, encryptionId=ec345834075, topicName=新希望)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jul 05 14:11:03 CST 2023, time=2023-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707246, encodeId=d4931e07246fa, content=<a href='/topic/show?id=fedc406085d' target=_blank style='color:#2F92EE;'>#困境#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40608, encryptionId=fedc406085d, topicName=困境)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a4631370697, createdName=ms2536978994064944, createdTime=Tue May 23 19:11:03 CST 2023, time=2023-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286123, encodeId=f3e91286123ed, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Jul 30 02:11:03 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554619, encodeId=70c1155461960, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Jul 30 02:11:03 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628525, encodeId=bfd51628525b6, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Sat Jul 30 02:11:03 CST 2022, time=2022-07-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1970041, encodeId=4a2e19e00413f, content=<a href='/topic/show?id=ec345834075' target=_blank style='color:#2F92EE;'>#新希望#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58340, encryptionId=ec345834075, topicName=新希望)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jul 05 14:11:03 CST 2023, time=2023-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707246, encodeId=d4931e07246fa, content=<a href='/topic/show?id=fedc406085d' target=_blank style='color:#2F92EE;'>#困境#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40608, encryptionId=fedc406085d, topicName=困境)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a4631370697, createdName=ms2536978994064944, createdTime=Tue May 23 19:11:03 CST 2023, time=2023-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286123, encodeId=f3e91286123ed, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Jul 30 02:11:03 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554619, encodeId=70c1155461960, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Jul 30 02:11:03 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628525, encodeId=bfd51628525b6, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Sat Jul 30 02:11:03 CST 2022, time=2022-07-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1970041, encodeId=4a2e19e00413f, content=<a href='/topic/show?id=ec345834075' target=_blank style='color:#2F92EE;'>#新希望#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58340, encryptionId=ec345834075, topicName=新希望)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jul 05 14:11:03 CST 2023, time=2023-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707246, encodeId=d4931e07246fa, content=<a href='/topic/show?id=fedc406085d' target=_blank style='color:#2F92EE;'>#困境#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40608, encryptionId=fedc406085d, topicName=困境)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a4631370697, createdName=ms2536978994064944, createdTime=Tue May 23 19:11:03 CST 2023, time=2023-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286123, encodeId=f3e91286123ed, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Jul 30 02:11:03 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554619, encodeId=70c1155461960, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Jul 30 02:11:03 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628525, encodeId=bfd51628525b6, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Sat Jul 30 02:11:03 CST 2022, time=2022-07-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1970041, encodeId=4a2e19e00413f, content=<a href='/topic/show?id=ec345834075' target=_blank style='color:#2F92EE;'>#新希望#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58340, encryptionId=ec345834075, topicName=新希望)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jul 05 14:11:03 CST 2023, time=2023-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707246, encodeId=d4931e07246fa, content=<a href='/topic/show?id=fedc406085d' target=_blank style='color:#2F92EE;'>#困境#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40608, encryptionId=fedc406085d, topicName=困境)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a4631370697, createdName=ms2536978994064944, createdTime=Tue May 23 19:11:03 CST 2023, time=2023-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286123, encodeId=f3e91286123ed, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Jul 30 02:11:03 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554619, encodeId=70c1155461960, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Jul 30 02:11:03 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628525, encodeId=bfd51628525b6, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Sat Jul 30 02:11:03 CST 2022, time=2022-07-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1970041, encodeId=4a2e19e00413f, content=<a href='/topic/show?id=ec345834075' target=_blank style='color:#2F92EE;'>#新希望#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58340, encryptionId=ec345834075, topicName=新希望)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jul 05 14:11:03 CST 2023, time=2023-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707246, encodeId=d4931e07246fa, content=<a href='/topic/show?id=fedc406085d' target=_blank style='color:#2F92EE;'>#困境#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40608, encryptionId=fedc406085d, topicName=困境)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a4631370697, createdName=ms2536978994064944, createdTime=Tue May 23 19:11:03 CST 2023, time=2023-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286123, encodeId=f3e91286123ed, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Jul 30 02:11:03 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554619, encodeId=70c1155461960, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Jul 30 02:11:03 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628525, encodeId=bfd51628525b6, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Sat Jul 30 02:11:03 CST 2022, time=2022-07-30, status=1, ipAttribution=)]

相关资讯

Clin Cancer Res:雷莫芦单抗治疗晚期胆道癌的疗效和安全性

雷莫芦单抗在晚期胆管癌患者中的耐受性良好,疗效不劣于已有化疗方案。

JGH: 胆囊切除术可降低复杂胆结石患者发生胆管癌的风险

胆结石是世界范围的常见病。在我国自然人群中,胆结石的发病率达10%左右。女性患者多见,尤其是较肥胖的女性,男女之比约为1∶2。胆结石是胆管(胆囊)癌的致病因素。

2022 ASCO:局部区域并发症的频率及其对胆管癌患者住院结局的影响

探讨胆管癌患者的结局是否会根据他们入院的局部区域并发症类型而有所不同。

JGH:胆囊切除术可降低复杂性胆结石患者患胆管癌的风险

胆结石在胆固醇胆石症患者的近亲中更经常发生,临床表现 1.胆囊结石 其症状取决于结石的大小和部位,以及有无阻塞和炎症等。部分胆囊结石患者终身无症状,即所谓隐性结石。

近千万亚洲人群10年队列研究:高血糖+喝酒,胆道癌越喝越有!发生风险可翻倍!

J Clin Oncol.:一项全国性队列研究显示,轻度至中度饮酒可增加糖尿病前期和糖尿病患者发生胆道癌的风险,但血糖正常时则不会

BMC Gastroenterology: 亚油酸通路紊乱导致肝内胆管结石诱变为肝内胆管癌

胆管癌是指源于肝外胆管包括肝门区至胆总管下端的胆管的恶性肿瘤。其病因可能与胆管结石、原发性硬化性胆管炎等疾病有关。